{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T10:29:08Z","timestamp":1688120948498},"reference-count":20,"publisher":"SLACK, Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2018,3]]},"abstract":"\n BACKGROUND AND OBJECTIVE:<\/jats:title>\n In the ASSESS study, patients with neovascular age-related macular degeneration transitioned from other anti-vascular endothelial growth factor therapies to intravitreous aflibercept (Eylea; Regeneron, Tarrytown, NY) injections (IAI). The purpose was to determine the 36-month outcomes following the change from a fixed 24-month IAI dosing regimen to a routine clinical practice regimen.<\/jats:p>\n <\/jats:sec>\n \n PATIENTS AND METHODS:<\/jats:title>\n Patients were treated with a fixed bimonthly regimen for the first 2 years. In the third year, patients were managed according to routine clinical practice.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n A total of 18 patients completed the 36 months and were considered for statistical analyses. At 36 months, a nonsignificant decrease of \u221237.8 \u03bcm in central subfield thickness and a nonsignificant gain of 5.8 letters from baseline were observed.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSION:<\/jats:title>\n Despite the significant visual and anatomical gains observed in the 2 years of fixed-dosing IAI, there was gradual decline in these improvements when patients were transitioned to a variable regimen.<\/jats:p>\n \n \n [\n Ophthalmic Surg Lasers Imaging Retina<\/jats:italic>\n . 2018;49:179\u2013185.]\n <\/jats:bold>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3928\/23258160-20180221-05","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T17:32:23Z","timestamp":1521480743000},"page":"179-185","source":"Crossref","is-referenced-by-count":2,"title":["36-Month Evaluation of Intravitreous Aflibercept Injection for Wet Age-Related Macular Degeneration in Patients Previously Treated With Ranibizumab or Bevacizumab"],"prefix":"10.3928","volume":"49","author":[{"given":"Felipe F.","family":"Conti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana Q.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justis P.","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Schachat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801537"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_3_1_5_2","unstructured":"Pollack JSAmerican Society of Retinal Specialists. 2014 Preferences and Trends Survey. http:\/\/www.asrs.org. Accessed January 16 2015."},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.01.024"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.08.009"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.10.004"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.011"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304798"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S87043"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2016.09.008"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01825-1"},{"key":"e_1_3_1_16_2","volume-title":"Eylea [package insert]","year":"2011","unstructured":"Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals; 2011."},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.046"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-303344"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.02.017"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.02.009"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.03.030"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.healio.com\/doiresolver?doi=10.3928\/23258160-20180221-05","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T19:46:12Z","timestamp":1683056772000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20180221-05"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.3928\/23258160-20180221-05"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20180221-05","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}